Cardiovascular angiotensin II type 1 receptor biased signaling: Focus on non-Gq-, non-βarrestin-dependent signaling
- PMID: 34662735
- DOI: 10.1016/j.phrs.2021.105943
Cardiovascular angiotensin II type 1 receptor biased signaling: Focus on non-Gq-, non-βarrestin-dependent signaling
Abstract
The physiological and pathophysiological roles of the angiotensin II type 1 (AT1) receptor, a G protein-coupled receptor ubiquitously expressed throughout the cardiovascular system, have been the focus of intense investigations for decades. The success of angiotensin converting enzyme inhibitors (ACEIs) and of angiotensin receptor blockers (ARBs), which are AT1R-selective antagonists/inverse agonists, in the treatment of heart disease is a testament to the importance of this receptor for cardiovascular homeostasis. Given the pleiotropic signaling of the cardiovascular AT1R and, in an effort to develop yet better drugs for heart disease, the concept of biased signaling has been exploited to design and develop biased AT1R ligands that selectively activate β-arrestin transduction pathways over Gq protein-dependent pathways. However, by focusing solely on Gq or β-arrestins, studies on AT1R "biased" signaling & agonism tend to largely ignore other non-Gq-, non β-arrestin-dependent signaling modalities the very versatile AT1R employs in cardiovascular tissues, including two very important types of signal transducers/regulators: other G protein types (e.g., Gi/o, G12/13) & the Regulator of G protein Signaling (RGS) proteins. In this review, we provide a brief overview of the current state of cardiovascular AT1R biased signaling field with a special focus on the non-Gq-, non β-arrestin-dependent signaling avenues of this receptor in the cardiovascular system, which usually get left out of the conversation of "biased" AT1R signal transduction.
Keywords: Angiotensin II type 1 receptor; Angiotensin receptor blocker; Biased signaling; Cardiovascular; G proteins; Regulator of G protein Signaling; β-arrestin.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
-
Adrenal angiotensin II type 1 receptor biased signaling: The case for "biased" inverse agonism for effective aldosterone suppression.Cell Signal. 2021 Jun;82:109967. doi: 10.1016/j.cellsig.2021.109967. Epub 2021 Feb 25. Cell Signal. 2021. PMID: 33640432 Review.
-
Biased agonism/antagonism at the AngII-AT1 receptor: Implications for adrenal aldosterone production and cardiovascular therapy.Pharmacol Res. 2017 Nov;125(Pt A):14-20. doi: 10.1016/j.phrs.2017.05.009. Epub 2017 May 13. Pharmacol Res. 2017. PMID: 28511989 Review.
-
Allosteric modulation of β-arrestin-biased angiotensin II type 1 receptor signaling by membrane stretch.J Biol Chem. 2014 Oct 10;289(41):28271-83. doi: 10.1074/jbc.M114.585067. Epub 2014 Aug 28. J Biol Chem. 2014. PMID: 25170081 Free PMC article.
-
Loss of biased signaling at a G protein-coupled receptor in overexpressed systems.PLoS One. 2023 Mar 24;18(3):e0283477. doi: 10.1371/journal.pone.0283477. eCollection 2023. PLoS One. 2023. PMID: 36961836 Free PMC article.
-
Heterotrimeric Gq proteins act as a switch for GRK5/6 selectivity underlying β-arrestin transducer bias.Nat Commun. 2022 Jan 25;13(1):487. doi: 10.1038/s41467-022-28056-7. Nat Commun. 2022. PMID: 35078997 Free PMC article.
Cited by
-
Angiotensin AT1A receptor signal switching in Agouti-related peptide neurons mediates metabolic rate adaptation during obesity.Cell Rep. 2023 Aug 29;42(8):112935. doi: 10.1016/j.celrep.2023.112935. Epub 2023 Aug 2. Cell Rep. 2023. PMID: 37540598 Free PMC article.
-
Gα12 and Gα13: Versatility in Physiology and Pathology.Front Cell Dev Biol. 2022 Feb 14;10:809425. doi: 10.3389/fcell.2022.809425. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35237598 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
